Ortho Development expands Trivicta hip stem to full U.S. launch

Ortho Development said on May 4, 2026, that it has begun the full commercial launch of its Trivicta hip stem, a cementless triple-taper femoral component for primary total hip arthroplasty, after what the company described as a controlled market introduction. The device is now being offered to U.S. surgeons and health systems through the company’s authorized distribution network. Trivicta previously received FDA 510(k) clearance in March 2024, with the company positioning it as an expansion of its primary hip portfolio. FDA clearance documents describe the stem as a titanium alloy, uncemented press-fit implant available in collared and collarless configurations, with hydroxyapatite and porous bead coatings. (prnewswire.com)

Why it matters: For veterinary professionals, this is mostly a watch item rather than a practice-changing development. The launch reflects continued investment in cementless fixation and implant design features meant to improve fit, stability, and bone preservation, trends that often influence how orthopedic innovation is discussed across species and specialties. In human arthroplasty, cementless femoral fixation remains the dominant approach in primary total hip arthroplasty, with AAOS reporting that cemented stems accounted for just 4.55% of elective primary THA procedures in the American Joint Replacement Registry summary, while other AAOS data have shown femoral stem utilization at about 80% cementless in 2021. (odev.com)

What to watch: Watch for surgeon uptake, any published early clinical data, and whether Ortho Development expands Trivicta-related education, indications, or supporting registry evidence over the next 12 months. (prnewswire.com)